Strand Bio Review: Historical Pricing and Audited Public Evidence
An independent Strand Bio review: 29 previously accepted price records remain as explicitly historical observations, and the September 7 public-markup audit of 83 reachable pages — including the catalog after researcher-login migrated there — detected no Strand Bio testing evidence.
Strand Bio remains a curated vendor on PeptideBenchmark because of a previously public, unusually legible price list. Those 29 accepted records remain available as dated historical observations, and they stay excluded from current offers, winners, medians, and Stack Builder until a fresh anonymous pricing capture replaces them. On the audited public research, compliance, and catalog markup, PeptideBenchmark detected no Strand Bio testing evidence a reader can inspect.
Both halves of that sentence are findings, and this review keeps them apart.
Reviewed July 30, 2026; public access and testing evidence re-audited September 7, 2026. PeptideBenchmark has no affiliate, coupon, sponsorship, or paid-placement relationship with Strand Bio. It does earn affiliate commissions from some other vendors on this site, including vendors a reader may reach from the links below; those relationships cannot change a trust band, an evidence score, or a finding. The current evidence finding covers pages available without an account, including catalog pages after the researcher-login route migrated to the public catalog. The vendor sells research-use-only products; this is an evidence and pricing review, not human-use guidance or medical advice.
The short version
When Strand Bio’s price list was publicly reachable, PeptideBenchmark captured eight category tables with product name, vial size, molecule class, price per vial, and checkout status. Every record carried one vial size in milligrams and one price. All 29 normalized to a price per milligram with zero deferrals. Those remain retained, dated rows rather than a restamped anonymous quote.
That is uncommon. Most catalogues lose rows somewhere.
The current public evidence review covered 83 publicly reachable research, compliance, and catalog pages, including pages linked outside the vendor’s primary public index. It checked page text, metadata, embedded page data, URL-bearing attributes, CSS and script literals, document frames, and downloadable resources for certificate, laboratory, purity, batch, verification, and testing signals. It does not claim to OCR otherwise unlabelled raster image pixels. The review also confirmed fourteen conventional certificate routes such as /coa, /lab-results, /certificates, and /verify returned exact 404 responses. No public PDF or detectable Strand Bio testing claim was found. Separately, 1 exact authentication gate reached from public links was checked: the partner feed returned its reviewed 401 approved-researcher response after the researcher-login route migrated to the public catalog. Catalog pages that used to sit behind that login were included in this absence sweep.
Strand Bio does not hide this. Its compliance page says it plainly: the vendor does not convert catalog specifications, disclaimers, or checkout availability into a testing claim.
Three near-misses are worth naming, because a keyword or URL sweep reports them as evidence and none is a Strand Bio testing claim. The only mention of a COA on the site is a source-note link to Simple Peptide’s COA page in one comparison article. A different comparison article links to Prime Peptides’ testing page. Separately, Strand Bio’s own compliance page and several catalog guides state that a batch-document link should appear only when it is tied to a real public product record — a description of how such a link would be presented. No public Strand Bio product record carries one.
Strand Bio's accepted pricing rows remain straightforward to compare as a dated capture. The audited public research, compliance, and catalog markup exposed no detectable identity, purity, or contamination evidence for an anonymous reader to weigh. Otherwise unlabelled image pixels may contain information PeptideBenchmark did not evaluate.
What the price list gets right
| Catalog result | Count | PB treatment |
|---|---|---|
| Previously captured catalog records | 29 | Retained from the formerly public price list |
| Comparable vial rows | 29 | Retained as dated history; excluded from current Pricing and Stack Builder offers |
| Deferred | 0 | Nothing comparable was left behind |
| Out of scope | 0 | No capsules, sprays, or IU-dosed items in the range |
The retained July price set runs $39 to $139 per vial across eight research categories. Normalized, the range is wider than the sticker prices suggest: Glutathione at $0.065/mg (750 mg) and NAD+ at $0.13/mg (1000 mg) at one end, Retatrutide at $11.90/mg, Cagrilintide at $12.90/mg, and IGF-1 DES at $99.00/mg (a 1 mg vial) at the other. These figures should be treated as the last accepted public observation, not a live anonymous quote.
Six records needed mapping before they could compare against the same molecule elsewhere. Two are vendor shorthand — MT-2 to Melanotan II, and Epithalon to the canonical Epitalon spelling — and the other four are spelling or capitalisation differences on blends and NAD+. One product, IGF-1 DES, is a compound the board had not carried before. It is not the same molecule as the IGF-1 LR3 already listed, so it enters as its own compound rather than being folded into a look-alike.
What is missing, precisely
It is worth being exact about the claim, because “no COAs” gets used loosely.
PeptideBenchmark did not find a certificate of analysis, a purity percentage, a batch or lot identifier, a laboratory name, or a verification code in the audited markup for any of the 83 publicly reachable pages reviewed on September 7. No public downloadable document or embedded testing resource was found. Of the 1 exact authentication gate reached from public links, the partner feed returned its reviewed 401 approved-researcher response after the researcher-login route migrated to the public catalog. This review makes no claim about otherwise unlabelled image pixels.
What this establishes: an anonymous reader was not offered detectable, inspectable testing evidence in the audited public markup, and PeptideBenchmark cannot vouch for identity or purity on the vendor’s behalf.
What this does not establish: that no testing occurred. We report what a vendor publishes. A vendor may test and simply not publish, and the absence of a public certificate is not proof of an untested product. It is proof that the question cannot be answered from the outside — which for a reader choosing between suppliers is a meaningful difference from a vendor whose certificates resolve at an issuing laboratory.
PeptideBenchmark rechecks the public absence on every trust review. A newly public page, document, testing claim, or formerly gated route enters review rather than being silently absorbed. Previously audited route identities also remain checked until they are still readable or return an exact 404/410 response.
How this affects the score
Strand Bio holds a None trust band and a 1.00 PeptideBenchmark evidence score after the September 7 review. That point comes from retained pricing coverage; there is no public testing-evidence contribution.
That gap is the score reflecting what a reader can verify publicly. It does not prove Strand Bio performs no testing. If public, source-linked evidence appears later, the trust review will route it for evaluation and the score can change.
For what the bands and scores measure, see how the vendor benchmark works.
Who this vendor suits
Readers comparing headline prices across a broad single-size catalogue, who intend to source testing evidence separately or ask for it directly.
It suits a reader who wants a publicly inspectable certificate considerably less well. For that, the COA database indexes vendors whose certificates are published and, in many cases, confirmable at the issuing laboratory — a different standard from what the audited Strand Bio public markup exposed.
The vendor is operated by WRAITH Supplements LLC and publishes a Westlake, Ohio address and phone number on its support page, so it is mapped on the peptide vendor map. Strand Bio also runs a large research library, five pages of which compare it with named competitors; none describe testing of Strand Bio’s own products.
Bottom line
Strand Bio’s retained prices are easy to compare. The audited public markup exposed no testing evidence to verify them against.
The price list was genuinely good work when it was public — complete, normalized, honest about checkout status, and comparable without guesswork. Every row was captured; the retained set now appears only as explicitly historical, access-gated observations. Very few catalogues manage that.
No testing evidence was detected on the audited anonymous public surface, and the vendor is upfront rather than implying testing in the public claims it does expose. Whether that trade is acceptable is a reader’s call. Anyone weighing a purchase on testing grounds should ask Strand Bio directly for batch documentation and evaluate any response on its own merits.
Readers can inspect the Strand Bio profile, compare retained dated price observations, or visit the official storefront.
Common questions
Does Strand Bio publish COAs?
No public COAs were found in the audited page markup. On September 7, PeptideBenchmark checked 83 publicly reachable research, compliance, and catalog pages, confirmed fourteen conventional certificate routes returned exact 404 responses, and verified 1 exact authentication gate reached from public links: the partner feed returned its reviewed 401 approved-researcher response after the researcher-login route migrated to the public catalog. No audited public page served a PDF or exposed a detectable Strand Bio testing claim. This finding does not describe otherwise unlabelled image pixels.
Does that mean Strand Bio products are untested?
No, and this distinction matters. PeptideBenchmark can only report what it can inspect on the anonymous public surface. Finding no public certificate in the audited markup establishes that an anonymous reader was not offered inspectable testing evidence there — it does not establish that no testing occurred or describe gated materials. A buyer who wants documentation should ask Strand Bio directly for batch paperwork and judge the answer themselves.
Why is Strand Bio's evidence score so low?
Because PeptideBenchmark found no public evidence to score. Strand Bio holds a None trust band and a 1.00 PeptideBenchmark evidence score after the September 7 public-surface review. The remaining point comes from retained pricing coverage, not testing evidence.
Is Strand Bio's pricing comparable to other vendors?
The 29 records captured while Strand Bio's price list was public all normalize to a price per milligram with no deferrals. PeptideBenchmark has not restamped those accepted rows as a new anonymous quote, so they remain a dated comparison even though catalog HTML is now publicly reachable.
Does PeptideBenchmark have an affiliate relationship with Strand Bio?
No. At the time of this review, PeptideBenchmark had no affiliate, coupon, sponsorship, or paid-placement relationship with Strand Bio. PeptideBenchmark does earn affiliate commissions from some other vendors it covers, including vendors a reader might reach from this page. Those relationships cannot change a trust band, an evidence score, or a finding.